https://www.selleckchem.com/products/PP242.html
These advances have led to the development of new vaccines against Salmonella which have or will soon be tested in clinical trials.Certolizumab pegol (CZP), the only Fc-free, PEGylated anti-tumor necrosis factor biologic agent. This study aims to investigate the effect and safety of CZP in moderate-to-severe chronic plaque psoriasis. We performed a retrospective observational analysis of the moderate-to-severe psoriasis patients under ceratolizumab pegol therapy. Primer endpoints were efficacy of CZP, defined as statistically significant
Like
Comment
Share
